An international, randomized, double-blind, placebo-controlled, study of valacyclovir for the suppression of herpes simplex virus type 2 genital herpes in newly diagnosed patients

Sexually Transmitted Diseases

Volumn 35, Issue 7, 2008, Pages 666-673

  Fife, Kenneth H ^a   Warren, Terri J ^b   Justus, Scott E ^c   Heitman, Catherine K ^c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Westover Heights Clinic   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VALACICLOVIR; ACICLOVIR; ANTIVIRUS AGENT; DRUG DERIVATIVE; VALINE;

ADULT; AGED; ARGENTINA; ARTICLE; BRAZIL; CANADA; CHILE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SCREENING; TREATMENT DURATION; UNITED STATES; UNSPECIFIED SIDE EFFECT; ADOLESCENT; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; TREATMENT OUTCOME;

ACYCLOVIR; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; BRAZIL; CANADA; CHILE; DOUBLE-BLIND METHOD; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HUMANS; MALE; MIDDLE AGED; RECURRENCE; TREATMENT OUTCOME; UNITED STATES; VALINE;

EID: 50649110554     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e31816d1f42     Document Type: Article

References (27)

1. Fife KH, Almekinder J, Ofner S. A comparison of one year of episodic or suppressive treatment of recurrent genital herpes with valacyclovir. Sex Transm Dis 2007; 34:297-301.
2. Romanowski B, Marina RB, Roberts JN. Patients' preference of valacyclovir once-daily suppressive therapy versus twice-daily episodic therapy for recurrent genital herpes-A randomized study. Sex Transm Dis 2003; 30:226-231.
3. Douglas JM, Critchlow C, Benedetti J, et al. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med 1984; 310:1551-1556.
4. Straus SE, Takiff HE, Seidlin M, et al. Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir. N Engl J Med 1984; 310:1545-1550.
5. Reitano M, Tyring S, Lang W, et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: A large-scale dose range-finding study. J Infect Dis 1998; 178:603-610.
6. Mertz GJ, Loveless MO, Levin MJ, et al. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women: A multicenter, double-blind, placebo-controlled trial. Arch Intern Med 1997; 157:343-349.
7. Diaz-Mitoma F, Sibbald RG, Shafran SD, et al. Oral famciclovir for the suppression of recurrent genital herpes: A randomized controlled trial. JAMA 1998; 280:887-892.
8. Romanowski B, Zdanowicz YM, Owens ST. In search of optimal herpes management and standard of care (INSIGHTS) physicians' and patients' perceptions of genital herpes. Sex Transm Infect 2008; 84:51-56.
9. Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med 1994; 121:847-854.
10. Lafferty WE, Coombs RW, Benedetti J, et al. Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. N Engl J Med 1987; 316:1444-1449.
11. Gupta R, Wald A, Krantz E, et al. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis 2004; 190:1374-1381.
12. Koelle DM, Benedetti J, Langenberg A, et al. Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes. Ann Intern Med 1992; 116:433-437.
13. Wald A, Corey L, Cone R, et al. Frequent genital herpes simplex virus 2 shedding in immunocompetent women-Effect of acyclovir treatment. J Clin Invest 1997; 99:1092-1097.
14. Handsfield HH, Warren T, Werner M, et al. Suppressive therapy with valacyclovir in early genital herpes: A pilot study of clinical efficacy and herpes-related quality of life. Sex Transm Dis 2007; 34:339-343.
15. Jerome KR, Huang ML, Wald A, et al. Quantitative stability of DNA after extended storage of clinical specimens as determined by realtime PCR. J Clin Microbiol 2002; 40:2609-2611.
16. Ryncarz AJ, Goddard J, Wald A, et al. Development of a high-throughput quantitative assay for detecting herpes simplex virus DNA in clinical samples. J Clin Microbiol 1999; 37:1941-1947.
17. Wald A, Huang ML, Carrell D, et al. Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: Comparison with HSV isolation in cell culture. J Infect Dis 2003; 188:1345-1351.
18. Collins P, Oliver NM. Sensitivity monitoring of herpes simplex virus isolates from patients receiving acyclovir. J Antimicrob Chemother 1986; 18(suppl B):103-112.
19. Goldberg LH, Kaufman R, Kurtz TO, et al. Long-term suppression of recurrent genital herpes with acyclovir: A 5-year benchmark. Arch Dermatol 1993; 129:582-587.
20. Fife K, Brennan CA, Dix LP. Once daily valacyclovir for reducing viral shedding in HSV-2 seropositive subjects newly diagnosed with genital herpes. Presented at the 17th International Society for STD Research, Seattle, WA, July 29 to August 1, 2007. Abstract #P-247.
21. Benedetti JK, Zeh J, Corey L. Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time. Ann Intern Med 1999; 131:14-20.
22. Pottage JC, Kessler HA. Herpes simplex virus resistance to acyclovir: Clinical relevance. Infect Agents Dis 1995; 4:115-124.
23. Reyes M, Shaik NS, Graber JM, et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch Intern Med 2003; 163: 76-80.
24. Villarreal EC. Current and potential therapies for the treatment of herpesvirus infections. Prog Drug Res 2001; 56:77-120.
25. Fife KH, Crumpacker CS, Mertz GJ, et al. Recurrence and resistance patterns of herpes simplex virus following cessation of ≥6 years of chronic acyclovir suppression. J Infect Dis 1994; 169:1338-1341.
26. Batalden K, Bria C, Biro FM. Genital herpes and the teen female. J Pediatr Adolesc Gynecol 2007; 20:319-321.
27. Kim HN, Wald A, Harris J, et al. Does frequency of genital herpes recurrences predict risk of transmission? Further analysis of the valacyclovir transmission study. Sex Transm Dis 2008; 35: 124-128.